Developing the system of quality measures for medical care assessment in patients with chronic heart failure: methodology and criteria (review)
Year: 2024, volume 20 Issue: №4 Pages: 425-435
Heading: Cardiology Article type: Review
Authors: Posnenkova О.М., Gridnev V.I.
Organization: Saratov State Medical University
Heading: Cardiology Article type: Review
Authors: Posnenkova О.М., Gridnev V.I.
Organization: Saratov State Medical University
Summary:
Objective: To develop a system of quality measures for monitoring the process and outcome of medical care in patients with chronic heart failure (CHF) in real clinical practice. Review methodology. The procedure for selecting indicators to monitor the treatment of cardiological patients proposed by О M. Posnenkova (2013) was applied. An analysis of the Russian Ministry of Health's clinical guidelines on CHF (2024) was conducted to determine the characteristics of the planned treatment outcomes and key measures with proven impact on outcomes. A systematic literature review using the PRISMA methodology was performed to identify therapeutic interventions that determine the achievement of results in real-world clinical practice. The PubMed and eLibrary databases were used. The search depth was from 2020 to 2024. Twenty-five sources were selected. Conclusion. In real clinical practice it is advisable to assess: 1) the proportion of patients with HF with reduced ejection fraction (EF) who have been prescribed quad-riple therapy (angiotensin-converting enzyme inhibitor/angiotensin receptor/angiotensin receptor neprilysin inhibitors + beta-blockers + aldosterone receptor antagonists + sodium/glucose cotransporter 2 inhibitors); 2) the proportion of patients with HF with preserved EF and HF with mildly reduced EF who have been prescribed sodium/glucose cotransporter 2 inhibitors; 3) the proportion of HF patients without adverse events (hospitalizations due to HF or death) over the past 12 months.
Bibliography:
1. Galyavich AS, Tereshchenko SN, Uskach TM, et al. 2024 Clinical practice guidelines for Chronic heart failure. Russian Journal of Cardiology. 2024; 29 (11): 6162. DOI: 10.15829/1560-4071-2024-6162. EDN WKIDLJ
2. Aktaa S, Polovina М, Rosano G, et al. European Society of Cardiology quality indicators for the care and outcomes of adults with heart failure. Developed by the Working Group for Heart Failure Quality Indicators in collaboration with the Heart Failure Association of the European Society of Cardiology. Eur J Heart Fail. 2022; 24 (1): 132-42. DOI: 10.1002/ejhf.2371
3. Spertus JA, Eagle KA, Krumholz HM, et al. American College of Cardiology and American Heart Association methodology for the selection and creation of performance measures for quantifying the quality of cardiovascular care. J Am Coll Cardiol. 2005; 45 (7): 1147-56. DOI: 10.1016/j.jacc.2005.03.011
4. Posnenkova OM, Kiselev AR, Popova YuV, et al. Methodology of clinical quality indicators for cardiovascular disease patients. Bulletin of Medical Internet Conferences. 2013; 3 (12): 1399-401.
5. Smirnova ЕА, Sedykh EV, Gorbova AV, et al. Assessment of the Clinical Profile and Approaches to the Diagnosis and Treatment of Patients Hospitalized with Acute Decompensation
of Heart Failure. I. P. Pavlov Russian Medical Biological Herald. 2022; 30 (2): 183-92. DOI: 10.17816/PAV-LOVJ81552
6. Vinogradova NG, Polyakov DS, Fomin IV. Analysis of mortality in patients with heart failure after decompensation during long-term follow-up in specialized medical care and in real clinical practice. Kardiologiia. 2020; 60 (4): 91-100. DOI: 10.18087/cardio.2020.4.n1014
7. Lebedeva NB, Parfenov PG, Ivanov VI, et al. External validation of a multivariate model for predicting the risk of death in patients with chronic heart failure and an implantable cardio-verter — defibrillator. Bulletin of Siberian Medicine. 2024; 23 (2): 74-82. DOI: 10.20538/1682-0363-2024-2-74-82
8. Lebedeva NB, Talibullin IV, Parfenov PG, Barbarash OL. Predictors of unfavorable prognosis in patients with heart failure after cardioverter-defibrillator implantation according to the prospective part of the Kuzbass Registry. Kardiologiia. 2024; 64 (4): 31-7. DOI: 10.18087/cardio.2024.4.n2370
9. Lebedeva NB, Talibullin IV, Parfenov PG, et al. Long-term outcomes in patients with an implanted cardioverter-defibrillator according to the Kuzbass registry. Kardiologiia. 2022; 62 (12): 57-63. DOI: 10.18087/cardio.2022.12.П2082
10. Lebedeva NB, Talibullin IV, Parfenov PG, et al. Factors associated with the risk of progression and decompensation of heart failure in patients with an implantable cardioverter-defibrillator. Russian Journal of Cardiology. 2024; 29 (3): 5619. DOI: 10.15829/1560-4071-2024-5619. EDN YUEMYV
11. Okunev IM, Kochergina AM, Kashtalap VV, Barbarash OL. Clinical portrait of a patient with acute decompensation of heart failure. Creative Cardiology. 2022; 16 (3): 385-93. DOI: 10.24022/1997-3187-2022-16-3-385-393
12. Larina VN, Leonova MV, Bondarenkova AA, Larin VG. Patient compliance and physicians' adherence to guidelines on heart failure with reduced ejection fraction. Cardiovascular Therapy and Prevention. 2020; 19 (2): 2398. DOI: 10.15829/1728-8800-2020-2398
13. Soloveva АЕ, Medvedev АЕ, Lubkovsky AV, et al. Total, age- and sexspecific mortality after discharge of patients with heart failure: the first large-scale cohort real-world study on Russian population. Russian Journal of Cardiology. 2024; 29 (6): 5940. DOI: 10.15829/1560-4071-2024-5940. EDN CTTQTF
14. Zhirov IV, Safronova NV, Osmolovskaya YuF, Tereshchenko SN. Prognostic value of atrial fibrillation in patients with heart failure and different left ventricular ejection fraction: Results of the multicenter RIF-CHF register. Russian Journal of Cardiology. 2021; 26 (1): 4200. DOI:10.15829/1560-4071-2021-4200
15. Fedotov PA, Simonenko MA, Sazonova YuV, et al. Mortality risk factors in patients who are in heart transplantation waiting list. South Russian Journal of Therapeutic Practice. 2022; 3 (2): 41-54.DOI: 10 .21886/2712-8156-2022-3-2-41-54
16. Vaduganathan М, Claggett Bl, Jhund PS, et al. Estimating lifetime benefits of comprehensive disease-modifying pharmacological therapies in patients with heart failure with reduced ejection fraction: A comparative analysis of three randomised controlled trials. Lancet. 2020; 396 (10244): 121-8. DOI: 10.1016/S0140-6736(20)30748-0
17. Polsinelli VB, Sun JL, Greene JS, et al. Hospital heart failure medical therapy score and associated clinical outcomes and costs. JAMA Cardiol. 2024; 9 (11): 1029-38. DOI:10.1001/ jamacardio.2024.2969
18. Tang AB, Ziaeian B, Butler J, et al. Global impact of optimal implementation of guideline-directed medical therapy in heart failure. JAMA Cardiol. 2024; 9 (12): 1154-58. DOI: 10.1001/jamacardio. 2024.3023
19. Xiang B, Zhang R, Wu X, Zhou X. Optimal pharmaco-logic treatment of heart failure with preserved and mildly reduced ejection fraction. A meta-analysis. JAMA Network Open. 2022; 5 (9): e2231963. DOI:10.1001/jamanetworkopen.2022.31963
20. Karlstrom P, PivodicA, Dahlstrom U, Fu M. Modern heart failure treatment is superior to conventional treatment across the left ventricular ejection spectrum: real-life data from the Swedish Heart Failure Registry 2013-2020. Clin Res Cardiol. 2024; 113 (9): 1355-68. DOI: 10.1007/s00392-024-02498-z
21. Park CS, Park J, Bae NY, et al. Characteristics, predictors, and clinical outcomes in heart failure with reduced ejection fraction according to a 1 -year left ventricular ejection fraction following Sacubitril/Valsartan treatment. J Am Heart Assoc. 2024; 13: e036763. DOI: 10.1161/JAHA.124.036763
22. Greene SJ, Choi S, Lippman SJ, et al. Clinical effectiveness of Sacubitril/Valsartan among patients hospitalized for heart failure with reduced ejection fraction. J Am Heart Assoc. 2021; 10:e021459. DOI: 10.1161/JAHA.121.021459
23. Tomasoni D, Pagnesi M, Colombo G, et al. Guideline-directed medical therapy in severe heart failure with reduced ejection fraction: An analysis from the HELP-HF registry. Eur J Heart Fail. 2024; 26 (2): 327-37. DOI: 10.1002/ejhf.3081
24. Wang Y, Gao T, Meng C, et al. Sodium-glucose co-transporter 2 inhibitors in heart failure with mildly reduced or preserved ejection fraction: an updated systematic review and meta-analysis. Eur J Med Res. 2022; 27 (1): 314. DOI: 10.1186/S40001 -022-00945-z
25. Guo W, Tian J, Wang Y, et al. Web-based dynamic no-mogram for predicting risk of mortality in heart failure with mildly reduced ejection fraction. Risk Manag Healthc Policy. 2024; 17: 1959-72. DOI: 10.2147/RMHPS474862
26. Shlyakhto EV, Belenkov YuN, Boytsov SA, et al. Prospective observational multicenter registry study of patients with heart failure in the Russian Federation (PRIORITET-CHF): rationale, objectives and design of the study. Russian Journal of Cardiology. 2023; 28 (6): 5456. DOI:10.15829/1560-4071-2023-5456. EDN LKSHVP
27. Malgie J, Clephas PRD, Brunner-La Rocca HP, et al. Guideline-directed medical therapy for HFrEF: sequencing strategies and barriers for life-saving drug therapy. Eur J Heart Fail. 2023; 28 (5): 1221-34. DOI: 10.1007/s10741-023-10325-2
28. Packer M, McMurray JJV. Rapid evidence-based sequencing of foundational drugs for heart failure and a reduced ejection fraction. Eur J Heart Fail. 2021; 23 (6): 882-94. DOI: 10.1002/ejhf.2149
29. Sharma A, Verma S, Bhatt DL, et al. Optimizing foundational therapies in patients with HFrEF. JACC Basic Transl Sci. 2022; 7 (5): 504-17. DOI: 10.1016/j.jacbts.2021.10.018
| Attachment | Size |
|---|---|
| 2024_04_425-435.pdf | 634.93 KB |
Русский
English